Earlier this year GSK also entered a collaboration with the U.S. Department of Energy and National Cancer Institute to accelerate pre-clinical drug development through use of advanced computational technologies.
The new deal with Exscientia will allow GSK to search for drug candidates for up to 10 disease-related targets. GSK will provide research funding and make payments of 33 million pounds ($43 million), if pre-clinical milestones are met.
ERGO, the data prediction models of Prolantix most likely are spot on. Sweet article. Excellent find.
News 
Market Data 
Discover 
AI
